Volume 18, Number 9—September 2012
CME ACTIVITY - Policy Review
Control of Fluoroquinolone Resistance through Successful Regulation, Australia
|Drug/route of administration||PBS listed indication||
Consumer cost in AU$
|Private market†||PBS GB||PBS CB|
|Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients||25.20||34.20||5.60||Yes|
|Bacterial gastroenteritis in severely immunocompromised patients|
|Infections proven to be caused by P. aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobial drugs|
|Joint and bone infections, epididymo-orchitis, prostatitis, or perichondritis of the pinna suspected or proven to be caused by gram-negative or -positive bacteria resistant to all other appropriate antimicrobial drugs|
|Treatment of chronic suppurative otitis media in Aborigines or Torres Strait Islanders >1 mo of age||24.51||19.38||5.60||No|
|Treatment of chronic suppurative otitis media in a patient <18 y of age with perforation of the tympanic membrane|
|Treatment of chronic suppurative otitis media in a patient <18 y of age with a grommet in situ|
|Acute bacterial enterocolitis; complicated urinary tract infection||31.68||17.16||5.60||Yes|
|No longer listed||70.65||NA||NA||No|
*PBS, Pharmaceutical Benefits Scheme; GB, general beneficiaries; CB, concessional beneficiaries, including pensioners; NA, no longer available in PBS.
†Price to consumer varies between retail outlets.
‡Data from 2011.
- Page created: August 17, 2012
- Page last updated: August 17, 2012
- Page last reviewed: August 17, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)